论文部分内容阅读
重症肌无力是1879年由Evb氏首次报告的一种以横纹肌易疲劳、无力为特征的疾病。每日内症状有波动性,常是上午轻下午重,多以眼睑下垂,复视为首发症状,继而可出现四肢无力,吞咽困难,严重时可因呼吸肌麻痹而致死。本病的发病率相当高,根据日本的全国性普查每10万人中有5人发病,发病年龄多为20～30岁的青壮年,对劳动力有严重影响,且最后常导致死亡。因此本病早就引起了医药界的重视。虽然本病的发现已近百年,但本病的治疗却长期停留在用新斯的明一类的抗胆硷酯
Myasthenia gravis was first reported by Evb in 1879 as a condition characterized by stubborn, feeble striated muscle. Fluctuations in the daily symptoms, often light afternoon heavy, drooping eyelids, diplopia as the first symptom, followed by weakness in the limbs, swallowing difficulties, serious cases may be due to respiratory muscle paralysis and death. The incidence of this disease is quite high. According to the national census of Japan, 5 out of every 100,000 people and the young adults aged 20 to 30 years of age have a serious impact on the labor force, and often result in death eventually. Therefore, the disease has aroused the medical community’s attention. Although the discovery of the disease has been nearly a century, but the treatment of this disease has long remained in the neostigmine class of anticholinergic